The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
I - Interstitial/parenchymal lung disease
Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
Pneumonitis (interstitial lung disease/ILD)
Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
Progression, acceleration or exacerbation of preexisting ILD/fibrosis
Progression or exacerbation of preexisting/underlying rheumatoid arthritis-associated ILD
II - Pulmonary edema - Acute lung injury - ARDS
III - Pulmonary/alveolar/airway hemorrhage/bleeding
IV - Airway involvement
V - Pleural and/or pericardial involvement
IX - Neuromuscular / CNS involvement - Disordered breathing (during sleep)
X - Systemic/Distant conditions, syndromes and reactions
Lupus - Lupus syndrome (see also Vd)
Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
Myopathy-Myositis-Polymyositis (see also under Xba)
Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive
Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)